Syntis Bio
Syntis Bio Raises $33M in Series A
Syntis Bio Raises $33M in Series A
Syntis Bio has successfully raised $33M in a Series A led by Cerberus Ventures.
Company Overview
Syntis Bio is a HealthTech company headquartered in Cambridge, MA, founded in 2022 with 50+ employees.
Developing oral therapies for obesity diabetes and rare diseases
Fundraising Details
- Amount Raised: $33M
- Round Type: Series A
- Date: 2025-06-14
- Investors: Cerberus Ventures
About Syntis Bio
Developing oral therapies for obesity diabetes and rare diseases The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Cambridge, MA
- Founded: 2022
- Team Size: 50+
- Industry: HealthTech
What This Means
This funding round demonstrates strong investor confidence in Syntis Bio's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Syntis Bio's successful fundraising reflects the strong fundamentals and growth potential in this space.
Looking Ahead
With this new capital, Syntis Bio is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2025-06-14. For more information about Syntis Bio, visit their headquarters at Cambridge, MA.
Company Info
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free